Combination of IFNL4 polymorphisms and ALT reduction at 4 week of treatment with PEG IFN and Ribavirin is a new selection tool to optimize antiviral treatment allocation in HCV patients with low stage fibrosis

被引：0

作者：

Figorilli, Francesco ^{[1
,5
]}

Onali, Simona ^{[1
]}

Catone, Stefania ^{[2
]}

Argentini, Claudio ^{[2
]}

Casu, Stefania ^{[1
]}

Balestrieri, Cinzia ^{[3
]}

Conti, Maria ^{[3
]}

Serra, Giancarlo ^{[3
]}

Casale, Michele ^{[1
]}

Pasetto, Maria Cristina ^{[1
]}

Matta, Laura ^{[1
]}

Barca, Lucia ^{[1
]}

Scioscia, Rosetta ^{[1
]}

Canini, Irene ^{[4
]}

Quaranta, Maria Giovanna ^{[2
]}

Genovese, Domenico ^{[2
]}

Vella, Stefano ^{[2
]}

Chessa, Luchino ^{[1
,3
]}

机构：

[1] Univ Cagliari, Ctr Study Liver Dis, Dept Med Sci M Aresu, Cagliari, Italy

[2] Ist Super Sanita, Dept Therapeut Res & Med Evaluat, I-00161 Rome, Italy

[3] AOU Cagliari, Dept Internal Med, Cagliari, Italy

[4] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy

[5] UCL Inst Liver & Digest Hlth, Liver Failure Grp, Ucl Med Sch, London, England

来源：

HEPATOLOGY | 2015年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1153

引用

页码：778A / 779A

页数：2

共 4 条

[1] ASSOCIATION OF IFNL4 GENOTYPE AND ALT DECREASE IS A NEW TOOL TO PREDICT VIRAL ERADICATION IN HCV SARDINIAN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 4, TREATED WITH PEG-IFNα AND RIBAVIRIN
Chessa, L.
Genovese, D.
Catone, S.
Figorilli, F.
Onali, S.
Argentini, C.
Balestrieri, C.
Conti, M.
Serra, G.
Barca, L.
Quaranta, M. G.
Canini, I.
Vella, S.
[J]. DIGESTIVE AND LIVER DISEASE, 2014, 46 : E48 - E49
[2] Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study
Boglione, Lucio
Cardellino, Chiara Simona
Cusato, Jessica
De Nicolo, Amedeo
Cariti, Giuseppe
Di Perri, Giovanni
D'Avolio, Antonio
[J]. INFECTION GENETICS AND EVOLUTION, 2017, 51 : 167 - 172
[3] PEG-IFN alfa-2a (40KDA) as a monotherapy or in combination with ribavirin significantly improve end of treatment response rate in HCV genotype 4 chronic active hepatitis (CAH) patients.
Shobokshi, O
Serebour, EK
Skakni, L
Tantawi, A
Mohamad, AQ
Sandokji, A
Al-Kayyal, B
Al-Momen, S
Akbar, H
Ayoola, A
Humaidah, A
Hussein, E
Khawajah, F
Al-Jasser, N
[J]. HEPATOLOGY, 2002, 36 (04) : 362A - 362A
[4] PEGYLATED INTERFERON LAMBDA (PEG-IFN-λ) PHASE 2 DOSE-RANGING, ACTIVE-CONTROLLED STUDY IN COMBINATION WITH RIBAVIRIN (RBV) FOR TREATMENT-NAiVE HCV PATIENTS (GENOTYPES 1, 2, 3 OR 4): SAFETY, VIRAL RESPONSE, AND IMPACT OF IL-28B HOST GENOTYPE THROUGH WEEK 12
Muir, Andrew J.
Lawitz, Eric
Ghalib, Reem H.
Sussman, Norman L.
Anderson, Frank
Everson, Gregory T.
Jacobson, Ira M.
Lopez-Talavera, Juan Carlos
Hillson, Jan L.
Gray, Todd E.
Fontana, David
Ramos, Eleanor L.
Rodriguez-Torres, Maribel
[J]. HEPATOLOGY, 2010, 52 (04) : 715A - 716A

← 1 →